1 | JURISDICTION AND VENUE 2 2. This Court has subject matter over plaintiff's claim pursuant to 15 U.S.C. §§ 45(a), 52, 3 and 53(b), and 28 U.S.C. §§ 1331, 1337(a) and 1345. 4 3. Venue in the Western District of Washington is proper under 15 U.S.C. § 53(b) and 28 5 U.S.C. § 1391(b), (c), and (d). 6 7 **PLAINTIFF** 8 4. Plaintiff Federal Trade Commission is an independent agency of the United States 9 Government created by statute. 15 U.S.C. §§ 41-58. The FTC enforces Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, which prohibit, respectively, deceptive acts or practices and false 10 11 advertisements for food, drugs, devices, services, or cosmetics, in or affecting commerce. The FTC is 12 authorized under Section 13(b) of the FTC Act, 15 U.S.C. § 53(b), to initiate federal district court proceedings to enjoin violations of the FTC Act, and to secure such equitable relief as may be 13 14 appropriate in each case. 15 16 **DEFENDANTS** 5. 17 Defendant Seville Marketing, Ltd. ("Seville") is a British Columbia, Canada 18 corporation, located at 3017 Mountain Highway, North Vancouver, British Columbia, Canada, with its 19 registered office located at 1199 Lynn Valley Road, North Vancouver, British Columbia, Canada. 20 Seville has advertised, marketed, promoted, offered for sale, distributed, or sold products that 21 purportedly test humans for infection with the human acquired immunodeficiency virus ("HIV"). 22 Seville transacts or has transacted business in the Western District of Washington and throughout the 23 United States. 6. 24 Defendant Gregory Stephen Wong is the owner and principal of Seville, and resides in 25 North Vancouver, British Columbia, Canada. Individually, or in concert with others, Wong directs,

controls, formulates, or participates in the acts and practices set forth in this Complaint. He transacts

or has transacted business in the Western District of Washington and throughout the United States.

26

27

28

COMMERCE

7. Defendants' course of trade is in or affecting commerce, within the meaning of Section 4 of the FTC Act, 15 U.S.C. § 44.

DEFENDANTS' BUSINESS PRACTICES

- 8. Since at least June 2001, and continuing thereafter, defendants have marketed "Discreet HIV/AIDS Tests" ("HIV test kits") via the Internet to consumers throughout the United States. These HIV test kits purportedly test for infection with the human immunodeficiency virus ("HIV") in humans. HIV is the virus that causes acquired immunodeficiency syndrome ("AIDS"), an infectious disease characterized by immune system failure.
- 9. The defendants market their HIV test kits via two interconnected Internet web sites, www.discreettest.com and www.aidshivtest.com. Defendant Seville is the registrant of both web sites. Defendant Wong is the administrator of the first web site and defendant Seville is the administrator of the second web site.
- 10. According to the defendants' Internet web sites, their HIV test kits are available for purchase only via the Internet. The web sites include links to two order forms, one labeled "US Orders" and one labeled "International Orders." The U.S. order form states that each kit costs "\$29.95 USD [United States dollars]." It offers three delivery options: "Regular," "FedEx Overnight Delivery," and "FedEx Overnight Saturday Delivery." Each delivery option has a different shipping cost, also in U.S. dollars. The Internet web sites also offer consumers the option to order by mail, by sending a money order in "US funds only" to Seville Marketing, Ltd., at its address in North Vancouver, British Columbia, Canada.
- 11. In the course of marketing their HIV test kits, defendants represent that their HIV test kits provide accurate results and that tests prove that their HIV test kits are 99.4% accurate at detecting the presence or absence of HIV antibodies. Through these Internet web sites, defendants make the following statements:
 - a. "Our HIV test gives you immediate, accurate, and 100% private results."

| 1 | b. " Discreet's accuracy, ease of use, and flexibility have made it a very popular |
|----|---|
| 2 | and sensitive alternative for AIDS/HIV testing" |
| 3 | c. "How accurate is the Discreet HIV testing kit? |
| 4 | If testing procedures are followed accurately and the test is taken at least twenty- |
| 5 | eight days after exposure to the HIV virus, the test results are 99.4% accurate. |
| 6 | Over the past two years we've had three independent studies done on Discreet |
| 7 | and our 99.4% accuracy rate is based upon these studies." |
| 8 | d. "Get accurate results in just three minutes." |
| 9 | |
| 10 | SECTIONS 5 AND 12 OF THE FTC ACT |
| 11 | 12. Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), prohibits deceptive acts or practices in |
| 12 | or affecting commerce. Section 12(a) of the FTC Act, 15 U.S.C. § 52(a), prohibits the dissemination of |
| 13 | any false advertisement in or affecting commerce for the purpose of inducing, or which is likely to |
| 14 | induce, the purchase of food, drugs, devices, services or cosmetics. For the purposes of Section 12 of |
| 15 | the FTC Act, defendants' HIV test kit constitutes a "device" as "device" is defined in Section 15 of the |
| 16 | FTC Act, 15 U.S.C. § 55. As set forth below, the defendants have engaged in and are continuing to |
| 17 | engage in violations of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, in connection |
| 18 | with the marketing and sale of their HIV test kits. |
| 19 | |
| 20 | DEFENDANTS' FTC ACT VIOLATIONS |
| 21 | COUNT I |
| 22 | 13. In numerous instances, defendants have represented, expressly or by implication, that |
| 23 | the Discreet HIV test kits accurately detect the presence or absence of HIV antibodies. |
| 24 | 14. In truth and in fact, the Discreet HIV test kits do not accurately detect the presence of or |
| 25 | absence of HIV antibodies. |
| 26 | 15. Therefore, the representation set forth in Paragraph 13 above is false or misleading and |
| 27 | constitutes a deceptive act or practice, and the making of false advertisements, in violation of Sections |
| 28 | 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. |

1 **COUNT II** 2 16. Defendants have represented, expressly or by implication, that tests prove that the 3 Discreet HIV test kits are 99.4% accurate at detecting the presence or absence of HIV antibodies. In truth and in fact, tests do not prove that the Discreet HIV test kits are 99.4% accurate 4 17. 5 at detecting the presence or absence of HIV antibodies. 18. 6 Therefore, the representation set forth in Paragraph 16 above is false or misleading and 7 constitutes a deceptive act or practice, and the making of false advertisements, in violation of Sections 8 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. 9 10 **INJURY** 11 19. Defendants' violations of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 12 52, have injured and continue to injure consumers as a result of defendants' unlawful acts or practices. In addition, defendants have been unjustly enriched as a result of their unlawful practices. Absent 13 14 injunctive relief by this Court, defendants are likely to continue to injure consumers, reap unjust 15 enrichment, and harm the public interest. 16 17 THIS COURT'S POWER TO GRANT RELIEF 18 20. Section 13(b) of the FTC Act, 15 U.S.C. § 53(b), empowers this Court to grant 19 injunctive and other ancillary relief, including redress, disgorgement, and restitution, to prevent and 20 remedy any violations of any provision of law enforced by the FTC. The court, in the exercise of its 21 equitable jurisdiction, may award other ancillary relief, including, but not limited to, recission of 22 contracts and restitution, and the disgorgement of ill-gotten gains, caused by the Defendants' law 23 violations. 24 25 PRAYER FOR RELIEF 26 WHEREFORE, Plaintiff FTC requests that this Court, as authorized by Section 13(b) of the 27 FTC Act, 15 U.S.C. § 53(b), and pursuant to its own equitable powers: 28

| 1 | (a) Permanently enjoin defendants from violating Sections 5(a) and 12 of the FTC Act, 15 | |
|----------|---|----|
| 2 | U.S.C. §§ 45(a) and 52, in connection with the offer, sale, advertising, or other promotion or | |
| 3 | distribution of HIV test kits; | |
| 4 | (b) Award the Commission all temporary and preliminary injunctive and ancillary relief that | at |
| 5 | may be necessary to avert the likelihood of consumer injury during the pendency of this action, and to | |
| 6 | preserve the possibility of effective final relief, including, but not limited to, preliminary injunctive | |
| 7 | relief; | |
| 8 | (c) Award such equitable relief as the Court finds necessary to redress injury to consumers | |
| 9 | resulting from the Defendants' violations of Sections 5(a) and 12 of the FTC Act, including, but not | |
| 10 | limited to, rescission of contracts and restitution, and the disgorgement of ill-gotten gains; and | |
| 11 | (d) Award the Plaintiff the costs of bringing this action, and such other equitable relief as | |
| 12 | the Court may determine to be just and proper. | |
| 13 | | |
| 14 | | |
| 15 | DATED: May 14, 2004 Respectfully submitted, | |
| 16 17 | WILLIAM E. KOVACIC General Counsel | |
| 18 | CHARLES A. HARWOOD Regional Director | |
| 19 | s/Nadine S. Samter | |
| 20 | NADINE S. SAMTER, WSBA #23881 915 Second Ave., Ste. 2896 | |
| 21 | Seattle, Washington 98174 Tel: (206) 220-4479 | |
| 22 | Fax: (206) 220-6366 | |
| 23 | JANET M. EVANS, DC Bar # 358467 KIAL S. YOUNG, DC Bar # 461348 | |
| 24 | 600 Pennsylvania Avenue, NW, Room NJ-3213, NJ-3249 Washington, D.C. 20580 | |
| 25 | Tel.: (202) 326-2125, -3525 Fax: (202) 326-3259 | |
| 26 | ATTORNEYS FOR PLAINTIFF | |
| 27 | FEDERAL TRADE COMMISSION | |
| 28 | | |